Charles River Laboratories Intl. Inc vs Corsair Gaming Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Corsair Gaming Inc trades at $13.63 (market cap $1.42B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 10× Corsair Gaming Inc's market cap, and Charles River Laboratories Intl. Inc is more actively traded (1,176,885 versus 1,160,938). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Corsair Gaming Inc for 25 Days on average.
| CRL | CRSR | |
|---|---|---|
Market Cap | $14.23B | $1.42B |
Volume | 1,176,885 | 1,160,938 |
Sector | Health | Technology |
52-Week High | $310.77 | $14.35 |
52-Week Low | $149.93 | $4.58 |
Typical Hold Time | 33 Days | 25 Days |
Enterprise Value | $17.06B | $1.41B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Corsair Gaming (CRSR) trades at $13.63, up 0.29% with a bullish technical signal. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.23 exceeding expectations by 228%. Recent product launches like the VOXARA microphone and strategic acquisitions demonstrate growth initiatives. Financials show improving cash flow trends with projected 2026 operating cash flow of $106 million, though net income margins remain thin at 2.53%.
CRSR presents a mixed outlook with strong earnings momentum and product innovation offset by valuation concerns at 42x P/E. Analyst consensus is cautious with 64% hold ratings and $12.40 price target below current levels. Key risks include competitive gaming peripherals market and execution of growth strategy. The stock's near-term direction hinges on Q3 earnings delivery and sustained margin improvement.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →